Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome

Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgica...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-03, Vol.11 (3), p.424
Main Authors: Wang, Shang-Yu, Wu, Chiao-En, Lai, Chun-Chi, Chen, Jen-Shi, Tsai, Chun-Yi, Cheng, Chi-Tung, Yeh, Ta-Sen, Yeh, Chun-Nan
Format: Article
Language:English
Subjects:
Atrophy
Computed tomography
Esophagus
Gastrointestinal surgery
Ileum
Imatinib
Jejunum
Laparoscopy
Laparotomy
Literature reviews
Medical imaging
Mutation
Patients
Rectum
Stomach
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073
cites cdi_FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073
container_end_page
container_issue 3
container_start_page 424
container_title Cancers
container_volume 11
creator Wang, Shang-Yu
Wu, Chiao-En
Lai, Chun-Chi
Chen, Jen-Shi
Tsai, Chun-Yi
Cheng, Chi-Tung
Yeh, Ta-Sen
Yeh, Chun-Nan
description Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a
doi_str_mv 10.3390/cancers11030424
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6468640</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2547503859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073</originalsourceid><addsrcrecordid>eNqFksFu3CAQhq2qVROlOfdWIfXSQ7YBg7HdQ6Uo2SaRVt1KSc7WGA9ZVja4gC3tA_a9yipplORSBBpgPn5mYLLsI6NfOa_pqQKr0AfGKKciF2-yw5yW-ULKWrx9Nj_IjkPY0tQ4Z6Us32cHnNZcSCoPsz-_vAsjqmhmJMsZ-gmicZY4TX6ig247zWAjuR7StjUtuQtIjCUrp6Dvd-Ssm_dBdOQSQvTO2IghgdCTm7Qckr2dBufDN7Icxg0EE0gSjxsk6zGavf9i8v-98YTcgMa4OyFgO7K2yvXu3qQIyHqKyg34IXunoQ94_GiPsrsfy9vzq8VqfXl9frZaKFGVccHbGgqEVhd5GoqrHKqya7XUUjIqVIVcY9kyrGRb605rwLJgHRNaSNbSkh9l3x90x6kdsFNoo4e-GX1Kxe8aB6Z56bFm09y7uZFCVlLQJPDlUcC731N6q2YwQWHfg0U3hSbPaeqUFkVCP79Ct27y6WkTVYiyoLwq6kSdPlAq_WPwqJ-CYbTZV0nzqkrSiU_Pc3ji_9UE_wtUhb-G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547503859</pqid></control><display><type>article</type><title>Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome</title><source>PubMed Central(OpenAccess)</source><source>ProQuest - Publicly Available Content Database</source><creator>Wang, Shang-Yu ; Wu, Chiao-En ; Lai, Chun-Chi ; Chen, Jen-Shi ; Tsai, Chun-Yi ; Cheng, Chi-Tung ; Yeh, Ta-Sen ; Yeh, Chun-Nan</creator><creatorcontrib>Wang, Shang-Yu ; Wu, Chiao-En ; Lai, Chun-Chi ; Chen, Jen-Shi ; Tsai, Chun-Yi ; Cheng, Chi-Tung ; Yeh, Ta-Sen ; Yeh, Chun-Nan</creatorcontrib><description>Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a &lt;10% change in the treatment response or a size decrease of less than 5 mm between two consecutive computed tomography scans. Primary tumors were located in the stomach (23/51; 45%), followed by the rectum (17/51; 33%), ileum/jejunum (9/51; 18%), and esophagus (2/51; 4%). The median maximal shrinkage time was 6.1 months, beyond which further treatment may not be beneficial. However, the maximal shrinkage time was 4.3 months for the stomach, 8.6 months for the small bowel and 6.9 months for the rectum. The R0 tumor resection rate in 27 patients after neoadjuvant imatinib and surgery was 81.5%, and 70.4% of resection procedures succeeded in organ preservation. However, 10 of 51 patients (19.6%) had complications following neoadjuvant imatinib use (six from imatinib and four from surgery). Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers11030424</identifier><identifier>PMID: 30934606</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Atrophy ; Computed tomography ; Esophagus ; Gastrointestinal surgery ; Ileum ; Imatinib ; Jejunum ; Laparoscopy ; Laparotomy ; Literature reviews ; Medical imaging ; Mutation ; Patients ; Rectum ; Stomach ; Surgery ; Tumors</subject><ispartof>Cancers, 2019-03, Vol.11 (3), p.424</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073</citedby><cites>FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073</cites><orcidid>0000-0002-1081-8805 ; 0000-0003-1514-3015 ; 0000-0001-9756-3974</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2547503859/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2547503859?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30934606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Shang-Yu</creatorcontrib><creatorcontrib>Wu, Chiao-En</creatorcontrib><creatorcontrib>Lai, Chun-Chi</creatorcontrib><creatorcontrib>Chen, Jen-Shi</creatorcontrib><creatorcontrib>Tsai, Chun-Yi</creatorcontrib><creatorcontrib>Cheng, Chi-Tung</creatorcontrib><creatorcontrib>Yeh, Ta-Sen</creatorcontrib><creatorcontrib>Yeh, Chun-Nan</creatorcontrib><title>Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a &lt;10% change in the treatment response or a size decrease of less than 5 mm between two consecutive computed tomography scans. Primary tumors were located in the stomach (23/51; 45%), followed by the rectum (17/51; 33%), ileum/jejunum (9/51; 18%), and esophagus (2/51; 4%). The median maximal shrinkage time was 6.1 months, beyond which further treatment may not be beneficial. However, the maximal shrinkage time was 4.3 months for the stomach, 8.6 months for the small bowel and 6.9 months for the rectum. The R0 tumor resection rate in 27 patients after neoadjuvant imatinib and surgery was 81.5%, and 70.4% of resection procedures succeeded in organ preservation. However, 10 of 51 patients (19.6%) had complications following neoadjuvant imatinib use (six from imatinib and four from surgery). Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.</description><subject>Atrophy</subject><subject>Computed tomography</subject><subject>Esophagus</subject><subject>Gastrointestinal surgery</subject><subject>Ileum</subject><subject>Imatinib</subject><subject>Jejunum</subject><subject>Laparoscopy</subject><subject>Laparotomy</subject><subject>Literature reviews</subject><subject>Medical imaging</subject><subject>Mutation</subject><subject>Patients</subject><subject>Rectum</subject><subject>Stomach</subject><subject>Surgery</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqFksFu3CAQhq2qVROlOfdWIfXSQ7YBg7HdQ6Uo2SaRVt1KSc7WGA9ZVja4gC3tA_a9yipplORSBBpgPn5mYLLsI6NfOa_pqQKr0AfGKKciF2-yw5yW-ULKWrx9Nj_IjkPY0tQ4Z6Us32cHnNZcSCoPsz-_vAsjqmhmJMsZ-gmicZY4TX6ig247zWAjuR7StjUtuQtIjCUrp6Dvd-Ssm_dBdOQSQvTO2IghgdCTm7Qckr2dBufDN7Icxg0EE0gSjxsk6zGavf9i8v-98YTcgMa4OyFgO7K2yvXu3qQIyHqKyg34IXunoQ94_GiPsrsfy9vzq8VqfXl9frZaKFGVccHbGgqEVhd5GoqrHKqya7XUUjIqVIVcY9kyrGRb605rwLJgHRNaSNbSkh9l3x90x6kdsFNoo4e-GX1Kxe8aB6Z56bFm09y7uZFCVlLQJPDlUcC731N6q2YwQWHfg0U3hSbPaeqUFkVCP79Ct27y6WkTVYiyoLwq6kSdPlAq_WPwqJ-CYbTZV0nzqkrSiU_Pc3ji_9UE_wtUhb-G</recordid><startdate>20190325</startdate><enddate>20190325</enddate><creator>Wang, Shang-Yu</creator><creator>Wu, Chiao-En</creator><creator>Lai, Chun-Chi</creator><creator>Chen, Jen-Shi</creator><creator>Tsai, Chun-Yi</creator><creator>Cheng, Chi-Tung</creator><creator>Yeh, Ta-Sen</creator><creator>Yeh, Chun-Nan</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1081-8805</orcidid><orcidid>https://orcid.org/0000-0003-1514-3015</orcidid><orcidid>https://orcid.org/0000-0001-9756-3974</orcidid></search><sort><creationdate>20190325</creationdate><title>Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome</title><author>Wang, Shang-Yu ; Wu, Chiao-En ; Lai, Chun-Chi ; Chen, Jen-Shi ; Tsai, Chun-Yi ; Cheng, Chi-Tung ; Yeh, Ta-Sen ; Yeh, Chun-Nan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Atrophy</topic><topic>Computed tomography</topic><topic>Esophagus</topic><topic>Gastrointestinal surgery</topic><topic>Ileum</topic><topic>Imatinib</topic><topic>Jejunum</topic><topic>Laparoscopy</topic><topic>Laparotomy</topic><topic>Literature reviews</topic><topic>Medical imaging</topic><topic>Mutation</topic><topic>Patients</topic><topic>Rectum</topic><topic>Stomach</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Shang-Yu</creatorcontrib><creatorcontrib>Wu, Chiao-En</creatorcontrib><creatorcontrib>Lai, Chun-Chi</creatorcontrib><creatorcontrib>Chen, Jen-Shi</creatorcontrib><creatorcontrib>Tsai, Chun-Yi</creatorcontrib><creatorcontrib>Cheng, Chi-Tung</creatorcontrib><creatorcontrib>Yeh, Ta-Sen</creatorcontrib><creatorcontrib>Yeh, Chun-Nan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Research Library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Shang-Yu</au><au>Wu, Chiao-En</au><au>Lai, Chun-Chi</au><au>Chen, Jen-Shi</au><au>Tsai, Chun-Yi</au><au>Cheng, Chi-Tung</au><au>Yeh, Ta-Sen</au><au>Yeh, Chun-Nan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2019-03-25</date><risdate>2019</risdate><volume>11</volume><issue>3</issue><spage>424</spage><pages>424-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a &lt;10% change in the treatment response or a size decrease of less than 5 mm between two consecutive computed tomography scans. Primary tumors were located in the stomach (23/51; 45%), followed by the rectum (17/51; 33%), ileum/jejunum (9/51; 18%), and esophagus (2/51; 4%). The median maximal shrinkage time was 6.1 months, beyond which further treatment may not be beneficial. However, the maximal shrinkage time was 4.3 months for the stomach, 8.6 months for the small bowel and 6.9 months for the rectum. The R0 tumor resection rate in 27 patients after neoadjuvant imatinib and surgery was 81.5%, and 70.4% of resection procedures succeeded in organ preservation. However, 10 of 51 patients (19.6%) had complications following neoadjuvant imatinib use (six from imatinib and four from surgery). Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30934606</pmid><doi>10.3390/cancers11030424</doi><orcidid>https://orcid.org/0000-0002-1081-8805</orcidid><orcidid>https://orcid.org/0000-0003-1514-3015</orcidid><orcidid>https://orcid.org/0000-0001-9756-3974</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2019-03, Vol.11 (3), p.424
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6468640
source PubMed Central(OpenAccess); ProQuest - Publicly Available Content Database
subjects Atrophy
Computed tomography
Esophagus
Gastrointestinal surgery
Ileum
Imatinib
Jejunum
Laparoscopy
Laparotomy
Literature reviews
Medical imaging
Mutation
Patients
Rectum
Stomach
Surgery
Tumors
title Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A20%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20Evaluation%20of%20Neoadjuvant%20Imatinib%20Use%20in%20Locally%20Advanced%20Gastrointestinal%20Stromal%20Tumors:%20Emphasis%20on%20the%20Optimal%20Duration%20of%20Neoadjuvant%20Imatinib%20Use,%20Safety,%20and%20Oncological%20Outcome&rft.jtitle=Cancers&rft.au=Wang,%20Shang-Yu&rft.date=2019-03-25&rft.volume=11&rft.issue=3&rft.spage=424&rft.pages=424-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers11030424&rft_dat=%3Cproquest_pubme%3E2547503859%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-3b9a5eabf52bf5c3c2a87dbf6f66104c8e3fe7b1e86b9fdffae751d14f461b073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2547503859&rft_id=info:pmid/30934606&rfr_iscdi=true